Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy

Ionizing radiation can have a wide range of impacts on tumor-immune interactions, which are being studied with the greatest interest and at an accelerating pace by the medical community. Despite its undeniable immunostimulatory potential, it clearly appears that radiotherapy as it is prescribed and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2024-06, Vol.30 (11), p.2317-OF16
Main Authors: Morel, Daphné, Robert, Charlotte, Paragios, Nikos, Grégoire, Vincent, Deutsch, Eric
Format: Article
Language:English
Subjects:
Animals
Humans
Immunotherapy
Immunotherapy - methods
Life Sciences
Neoplasms
Neoplasms - immunology
Neoplasms - radiotherapy
Radiation Oncology
Radiotherapy
Radiotherapy - adverse effects
Radiotherapy - methods
Reviews
Translational Research, Biomedical
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page OF16
container_issue 11
container_start_page 2317
container_title Clinical cancer research
container_volume 30
creator Morel, Daphné
Robert, Charlotte
Paragios, Nikos
Grégoire, Vincent
Deutsch, Eric
description Ionizing radiation can have a wide range of impacts on tumor-immune interactions, which are being studied with the greatest interest and at an accelerating pace by the medical community. Despite its undeniable immunostimulatory potential, it clearly appears that radiotherapy as it is prescribed and delivered nowadays often alters the host's immunity toward a suboptimal state. This may impair the full recovery of a sustained and efficient antitumor immunosurveillance posttreatment. An emerging concept is arising from this awareness and consists of reconsidering the way of designing radiation treatment planning, notably by taking into account the individualized risks of deleterious radio-induced immune alteration that can be deciphered from the planned beam trajectory through lymphocyte-rich organs. In this review, we critically appraise key aspects to consider while planning immunologically fitted radiotherapy, including the challenges linked to the identification of new dose constraints to immune-rich structures. We also discuss how pharmacologic immunomodulation could be advantageously used in combination with radiotherapy to compensate for the radio-induced loss, for example, with (i) agonists of interleukin (IL)2, IL4, IL7, IL9, IL15, or IL21, similarly to G-CSF being used for the prophylaxis of severe chemo-induced neutropenia, or with (ii) myeloid-derived suppressive cell blockers.
doi_str_mv 10.1158/1078-0432.CCR-23-3632
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11145173</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2956682581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-2c8f55af157b74f78095822fbd4a571c89e7c02b3424f41e54cb5e69cc2903913</originalsourceid><addsrcrecordid>eNpdkU1L5TAUhoM4qOP4E5QudVEnn026EineUbggiLOYVUjT1BtJk5qkwv33tlwVnVXCeT8OhweAUwQvEWLiN4JclJASfNk0DyUmJakI3gNHiDFeElyx_fn_4TkEP1N6hhBRBOkBOCSCci4wPQL_HqPyyalsg1euWMXgszUxFcp3ReOst3oe349jiHnydtZSEfribhgmH1x4WmS3LVY2Z9MVD6qzIW9MVOP2F_jRK5fMyft7DP6ubh6b23J9_-euuV6XmmCaS6xFz5jqEeMtpz0XsGYC477tqGIcaVEbriFuCcW0p8gwqltmqlprXENSI3IMrna949QOptPG56icHKMdVNzKoKz8rni7kU_hVSKEKEOczA0Xu4bNf7nb67VcZpBWGHFOX5dt5-_bYniZTMpysEkb55Q3YUoS16yqBGZisbKdVceQUjT9ZzeCcmEoFz5y4SNnhhITuTCcc2dfD_pMfUAjb7JamPI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956682581</pqid></control><display><type>article</type><title>Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy</title><source>Freely Accessible Science Journals - check A-Z of ejournals</source><creator>Morel, Daphné ; Robert, Charlotte ; Paragios, Nikos ; Grégoire, Vincent ; Deutsch, Eric</creator><creatorcontrib>Morel, Daphné ; Robert, Charlotte ; Paragios, Nikos ; Grégoire, Vincent ; Deutsch, Eric</creatorcontrib><description>Ionizing radiation can have a wide range of impacts on tumor-immune interactions, which are being studied with the greatest interest and at an accelerating pace by the medical community. Despite its undeniable immunostimulatory potential, it clearly appears that radiotherapy as it is prescribed and delivered nowadays often alters the host's immunity toward a suboptimal state. This may impair the full recovery of a sustained and efficient antitumor immunosurveillance posttreatment. An emerging concept is arising from this awareness and consists of reconsidering the way of designing radiation treatment planning, notably by taking into account the individualized risks of deleterious radio-induced immune alteration that can be deciphered from the planned beam trajectory through lymphocyte-rich organs. In this review, we critically appraise key aspects to consider while planning immunologically fitted radiotherapy, including the challenges linked to the identification of new dose constraints to immune-rich structures. We also discuss how pharmacologic immunomodulation could be advantageously used in combination with radiotherapy to compensate for the radio-induced loss, for example, with (i) agonists of interleukin (IL)2, IL4, IL7, IL9, IL15, or IL21, similarly to G-CSF being used for the prophylaxis of severe chemo-induced neutropenia, or with (ii) myeloid-derived suppressive cell blockers.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-23-3632</identifier><identifier>PMID: 38477824</identifier><language>eng</language><publisher>United States: American Association for Cancer Research</publisher><subject>Animals ; Humans ; Immunotherapy ; Immunotherapy - methods ; Life Sciences ; Neoplasms ; Neoplasms - immunology ; Neoplasms - radiotherapy ; Radiation Oncology ; Radiotherapy ; Radiotherapy - adverse effects ; Radiotherapy - methods ; Reviews ; Translational Research, Biomedical</subject><ispartof>Clinical cancer research, 2024-06, Vol.30 (11), p.2317-OF16</ispartof><rights>2024 The Authors; Published by the American Association for Cancer Research.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2024 The Authors; Published by the American Association for Cancer Research 2024 American Association for Cancer Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-9121-4973 ; 0000-0001-8838-1343 ; 0000-0002-9668-4763 ; 0000-0002-8223-3697 ; 0000-0001-8604-4271</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38477824$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04621774$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Morel, Daphné</creatorcontrib><creatorcontrib>Robert, Charlotte</creatorcontrib><creatorcontrib>Paragios, Nikos</creatorcontrib><creatorcontrib>Grégoire, Vincent</creatorcontrib><creatorcontrib>Deutsch, Eric</creatorcontrib><title>Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Ionizing radiation can have a wide range of impacts on tumor-immune interactions, which are being studied with the greatest interest and at an accelerating pace by the medical community. Despite its undeniable immunostimulatory potential, it clearly appears that radiotherapy as it is prescribed and delivered nowadays often alters the host's immunity toward a suboptimal state. This may impair the full recovery of a sustained and efficient antitumor immunosurveillance posttreatment. An emerging concept is arising from this awareness and consists of reconsidering the way of designing radiation treatment planning, notably by taking into account the individualized risks of deleterious radio-induced immune alteration that can be deciphered from the planned beam trajectory through lymphocyte-rich organs. In this review, we critically appraise key aspects to consider while planning immunologically fitted radiotherapy, including the challenges linked to the identification of new dose constraints to immune-rich structures. We also discuss how pharmacologic immunomodulation could be advantageously used in combination with radiotherapy to compensate for the radio-induced loss, for example, with (i) agonists of interleukin (IL)2, IL4, IL7, IL9, IL15, or IL21, similarly to G-CSF being used for the prophylaxis of severe chemo-induced neutropenia, or with (ii) myeloid-derived suppressive cell blockers.</description><subject>Animals</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Life Sciences</subject><subject>Neoplasms</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - radiotherapy</subject><subject>Radiation Oncology</subject><subject>Radiotherapy</subject><subject>Radiotherapy - adverse effects</subject><subject>Radiotherapy - methods</subject><subject>Reviews</subject><subject>Translational Research, Biomedical</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdkU1L5TAUhoM4qOP4E5QudVEnn026EineUbggiLOYVUjT1BtJk5qkwv33tlwVnVXCeT8OhweAUwQvEWLiN4JclJASfNk0DyUmJakI3gNHiDFeElyx_fn_4TkEP1N6hhBRBOkBOCSCci4wPQL_HqPyyalsg1euWMXgszUxFcp3ReOst3oe349jiHnydtZSEfribhgmH1x4WmS3LVY2Z9MVD6qzIW9MVOP2F_jRK5fMyft7DP6ubh6b23J9_-euuV6XmmCaS6xFz5jqEeMtpz0XsGYC477tqGIcaVEbriFuCcW0p8gwqltmqlprXENSI3IMrna949QOptPG56icHKMdVNzKoKz8rni7kU_hVSKEKEOczA0Xu4bNf7nb67VcZpBWGHFOX5dt5-_bYniZTMpysEkb55Q3YUoS16yqBGZisbKdVceQUjT9ZzeCcmEoFz5y4SNnhhITuTCcc2dfD_pMfUAjb7JamPI</recordid><startdate>20240603</startdate><enddate>20240603</enddate><creator>Morel, Daphné</creator><creator>Robert, Charlotte</creator><creator>Paragios, Nikos</creator><creator>Grégoire, Vincent</creator><creator>Deutsch, Eric</creator><general>American Association for Cancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9121-4973</orcidid><orcidid>https://orcid.org/0000-0001-8838-1343</orcidid><orcidid>https://orcid.org/0000-0002-9668-4763</orcidid><orcidid>https://orcid.org/0000-0002-8223-3697</orcidid><orcidid>https://orcid.org/0000-0001-8604-4271</orcidid></search><sort><creationdate>20240603</creationdate><title>Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy</title><author>Morel, Daphné ; Robert, Charlotte ; Paragios, Nikos ; Grégoire, Vincent ; Deutsch, Eric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-2c8f55af157b74f78095822fbd4a571c89e7c02b3424f41e54cb5e69cc2903913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Life Sciences</topic><topic>Neoplasms</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - radiotherapy</topic><topic>Radiation Oncology</topic><topic>Radiotherapy</topic><topic>Radiotherapy - adverse effects</topic><topic>Radiotherapy - methods</topic><topic>Reviews</topic><topic>Translational Research, Biomedical</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morel, Daphné</creatorcontrib><creatorcontrib>Robert, Charlotte</creatorcontrib><creatorcontrib>Paragios, Nikos</creatorcontrib><creatorcontrib>Grégoire, Vincent</creatorcontrib><creatorcontrib>Deutsch, Eric</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morel, Daphné</au><au>Robert, Charlotte</au><au>Paragios, Nikos</au><au>Grégoire, Vincent</au><au>Deutsch, Eric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2024-06-03</date><risdate>2024</risdate><volume>30</volume><issue>11</issue><spage>2317</spage><epage>OF16</epage><pages>2317-OF16</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Ionizing radiation can have a wide range of impacts on tumor-immune interactions, which are being studied with the greatest interest and at an accelerating pace by the medical community. Despite its undeniable immunostimulatory potential, it clearly appears that radiotherapy as it is prescribed and delivered nowadays often alters the host's immunity toward a suboptimal state. This may impair the full recovery of a sustained and efficient antitumor immunosurveillance posttreatment. An emerging concept is arising from this awareness and consists of reconsidering the way of designing radiation treatment planning, notably by taking into account the individualized risks of deleterious radio-induced immune alteration that can be deciphered from the planned beam trajectory through lymphocyte-rich organs. In this review, we critically appraise key aspects to consider while planning immunologically fitted radiotherapy, including the challenges linked to the identification of new dose constraints to immune-rich structures. We also discuss how pharmacologic immunomodulation could be advantageously used in combination with radiotherapy to compensate for the radio-induced loss, for example, with (i) agonists of interleukin (IL)2, IL4, IL7, IL9, IL15, or IL21, similarly to G-CSF being used for the prophylaxis of severe chemo-induced neutropenia, or with (ii) myeloid-derived suppressive cell blockers.</abstract><cop>United States</cop><pub>American Association for Cancer Research</pub><pmid>38477824</pmid><doi>10.1158/1078-0432.CCR-23-3632</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-9121-4973</orcidid><orcidid>https://orcid.org/0000-0001-8838-1343</orcidid><orcidid>https://orcid.org/0000-0002-9668-4763</orcidid><orcidid>https://orcid.org/0000-0002-8223-3697</orcidid><orcidid>https://orcid.org/0000-0001-8604-4271</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2024-06, Vol.30 (11), p.2317-OF16
issn 1078-0432
1557-3265
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11145173
source Freely Accessible Science Journals - check A-Z of ejournals
subjects Animals
Humans
Immunotherapy
Immunotherapy - methods
Life Sciences
Neoplasms
Neoplasms - immunology
Neoplasms - radiotherapy
Radiation Oncology
Radiotherapy
Radiotherapy - adverse effects
Radiotherapy - methods
Reviews
Translational Research, Biomedical
title Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T14%3A33%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Translational%20Frontiers%20and%20Clinical%20Opportunities%20of%20Immunologically%20Fitted%20Radiotherapy&rft.jtitle=Clinical%20cancer%20research&rft.au=Morel,%20Daphn%C3%A9&rft.date=2024-06-03&rft.volume=30&rft.issue=11&rft.spage=2317&rft.epage=OF16&rft.pages=2317-OF16&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-23-3632&rft_dat=%3Cproquest_pubme%3E2956682581%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c324t-2c8f55af157b74f78095822fbd4a571c89e7c02b3424f41e54cb5e69cc2903913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2956682581&rft_id=info:pmid/38477824&rfr_iscdi=true